As central neuron system (CNS) cancers, astrocytomas are considered as common glial tumors (
1). Grade II (diffused astrocytoma) of this disease is characterized by slow developing tumor¸ considerable cell differentiation, and affinity to malignancy evolution (
2). An investigation indicates that grade II astrocytoma frequently is diagnosed in 35-year-old patients (range of 20 - 45) (
3). Anaplastic astrocytoma (grade III) is more malignant glioma than grade II (
4). One year and 5 years survival for anaplastic astrocytoma patients is estimated at 75% and 25%, respectively (
5). Low-grade gliomas (grade II gliomas) in adults include 3 groups as astrocytomas, oligodendrogliomas, and oligo-astrocytomas. Differences between the introduced groups are arisen from cellular origination of them. The low-grade disease tends to convert into higher grades (grades III and IV) (
6). As it is reported, mutation frequency in astrocytoma grade III for isocitrate dehydrogenase 1 (IDH1), alpha-thalassemia/mental retardation syndrome, nondeletion type, X-linked (ATRX), and Tumor protein 53(TP53) genes are as 75%, 63%, and 82%, respectively (
7). Details of up-regulation of ribosomal proteins S2, 8, S18, and L37A and down-regulation of apolipoprotein D (APOD), Sortilin-related receptor, L(DLR class) A (SORL1), SPARC (Osteonectin), Cwcv and Kazal like domains proteoglycan 2 (SPOCK2), protease, serine, 11 (PRSS11), DNA-binding protein inhibitor ID-3 (ID3) genes in the higher grades of asrtrocytoma are reported by MacDonald et al. (
8). Kunkle et al. investigation displayed that deregulation of collagen type IV A1(COL4A1), epidermal growth factor receptor (EGFR), basic transcription factor 3(BTF3), MAGUK p55 subfamily member 2 (MPP2), RAS oncogene GTPases 31 (RAB31), cyclin-dependent kinase 4 (CDK4), cluster of differentiation 99 (CD99), annexin A2 (ANXA2), DNA topoisomerase II alpha (TOP2A), and SERPINE1 mRNA binding protein 1 (SERBP1) genes is related to the high grade of astrocytoma. They showed that except MPP2, the other genes were up-regulated (
9). Recently, the screening of numerous genes to find restricted numbers of the critical genes, which are involved in diseases via PPI network analysis, has attracted the attention of researchers (
10-
12). Since the progression of lower grades of astrocytoma to higher grades is accompanied by difficulty of treatment and reduction of survival rate, here DEGs between grades II and III astrocytoma are investigated via PPI network analysis. The critical genes and related biological terms will determine to introduce therapeutic and diagnostic possible biomarkers.